Existing treatments against drug addiction are often ineffective due to the complexity of the networks 12 of protein-drug and protein-protein interactions (PPIs) that mediate the development of drug 13 addiction and related neurobiological disorders. There is an urgent need for understanding the 14 molecular mechanisms that underlie drug addiction toward designing novel preventive or therapeutic 15 strategies. The rapidly accumulating data on addictive drugs and their targets as well as advances in 16 machine learning methods and computing technology now present an opportunity to systematically 17 mine existing data and draw inferences on potential new strategies. To this aim, we carried out a 18 comprehensive analysis of cellular pathways implicated in a diverse set of 50 drugs of abuse using 19
Introduction 30
Drug addiction is a chronic relapsing disorder characterized by compulsive, excessive, and self-31 damaging use of drugs of abuse. It is a debilitating condition that potentially leads to serious 32 physiological injury, mental disorder and death, resulting in major health and social economic 33 impacts worldwide (Nestler, 2013 ; Koob and Volkow, 2016) . Substances with diverse chemical 34 structures and mechanisms of action are known to cause addiction. Except for alcohol and tobacco, 35 substances of abuse are commonly classified into six groups based on their primary targets or effects: 36 This is a provisional file, not the final typeset article cannabinoids (e.g. cannabis), opioids (e.g. morphine, heroin, fentanyl), central nervous system (CNS) 37 depressants (e.g. pentobarbital, diazepam), CNS stimulants (e.g. cocaine, amphetamine), 38
hallucinogens (e.g. ketamine, lysergic acid diethylamide) and anabolic steroids (e.g. nandrolone, 39 oxymetholone). 40
The primary actions of drugs of abuse have been well studied. In spite of the pleiotropy and 41 heterogeneity of drugs of abuse, they share similar phenotypes: from acute intoxication to chronic 42 dependence (Taylor et al., 2013) , the reinforcement shift from positive to negative through a three-43 stage cycle involving binge/intoxication, withdrawal/negative effect, and preoccupation/anticipation 44 . Notably, virtually all drugs of abuse augment dopaminergic transmission 45 in the reward system (Wise, 1996) . However, the detailed cellular pathways of addiction processes 46 are still far from known. For example, cocaine acts primarily as an inhibitor of dopamine (DA) 47 transporter (DAT) and results in DA accumulation in the synapses of DA neurons (Shimada et al., 48 1991; Volkow et al., 1997) . However, it has been shown that DA accumulation per se is not 49 sufficient to account for the rewarding process associated with cocaine addiction; serotonin (5-HT) 50 and noradrenaline/norepinephrine (NE) also play important roles (Rocha et al., 1998; Sora et al., 51 1998) . Another example is ketamine, a nonselective antagonist for N-methyl-d-aspartate (NMDA) 52 receptor (NMDAR), notably most effective in the amygdala and hippocampal regions of neurons 53 (Collingridge et al., 1983) . In addition to its primary action, ketamine affects a number of other 54 neurotransmitter receptors, including sigma-1 (Mendelsohn et al., 1985) , substance P (Okamoto et  55 al., 2003), opioid (Hustveit et al., 1995) , muscarinic acetylcholine (mACh) (Hirota et al., 2002) , 56 nicotinic acetylcholine (nACh) (Coates and Flood, 2001), serotonin (Kapur and Seeman, 2002) , and 57 γ-aminobutyric acid (GABA) receptors (Hevers et al., 2008) . The promiscuity of drugs of abuse 58
brings an additional layer of complexity, which prevents the development of efficient treatment 59 against drug addiction. 60
In recent years there has been significant progress in the characterization of drug/target/pathway 61 relations driven by the accumulation of drug-target interactions and pathways data, as well as the 62 development of machine learning, in silico genomics, chemogenomics and quantitative systems 63 pharmacology (QSP) tools. Several innovative studies started to provide valuable information on 64 substance abuse targets and pathways. For example, Li knowledgebases focused on G-protein coupled receptors (GPCRs) related to drugs of abuse in 71 general (Xie et al., 2014) , and cannabinoids in particular (Xie et al., 2016) . Notably, these studies 72 have shed light on selected categories or subgroups of drugs. There is a need to understand the 73 intricate couplings between multiple pathways implicated in the cellular response to drugs of abuse, 74
identify mechanisms common to various categories of drugs while distinguishing those unique to 75 selected categories. 76
We undertake here such a systems-level approach using a dataset composed of six different 77 categories of drugs of abuse. Following a QSP approach proposed earlier (Stern et al., 2016) , we 78 provide a comprehensive, unbiased glimpse of the complex mechanisms implicated in addiction. 79
Specifically, a set of 50 drugs of abuse with a diversity in chemical structures and pharmacological 80 actions were collected as probes, and the known targets of these drugs as well as the targets predicted 81 using our probabilistic matrix factorization (PMF) method (Cobanoglu et al., 2013) were analyzed to 82 infer biological pathways associated with drug addiction. Our analysis yielded 142 known and 48  83  predicted targets and 173 pathways permitting us to identify both generic mechanisms regulating the  84  responses to drug abuse as well as specific mechanisms associated with selected categories, which  85 could both facilitate the development of auxiliary agents for treatment of addiction. 86
A key step in our approach is to identify the targets for drugs of abuse. 
Selection of drugs of abuse and their known targets 108
We selected as input 50 drugs commonly known as drugs of abuse using two basic criteria: (i) 109 diversity in terms of structure and mode of action, and (ii) availability of information on at least one 110 human target protein in DrugBank v5 (Wishart et al., 2018) text-mining, prediction, and a combination score of the previous four, each ranging from 0 to 1. We 119 selected the human protein targets with experimental confidence scores of 0.4 or higher. 120
Supplementary Table 2 summarizes the 142 targets we identified as well as the associated 445  121 drug-target interactions. 122
Structure-based and interaction-pattern-based similarities between pairs of drugs were evaluated 123 using two different criteria. The former was based on structure-based distance calculated as the 124
Tanimoto distance between their 2D structure fingerprints. The Tanimoto distances were evaluated 125 using Python RDKit suite (RDKit: Open-Source Cheminformatics Software. https://www.rdkit.org/). 126 This is a provisional file, not the final typeset article Similarities based on their interactions patterns with known targets were evaluated by evaluating 127 target-based distances. To this aim, we represented each drug i by a 142-dimensional 'target vector' 128 d i , the entries of which represent the known targets and are assigned values of 0 or 1, depending on 129 the existence/observation of an interaction between the corresponding target and drug i. Interaction-130 pattern similarities between drug pairs i and j were evaluated by calculating the correlation cosine 131 cos(d i . d j ) = (d i . d j ) / (|d i | |d j |) between these vectors, and the corresponding cosine distance is [1 -132 cos(d i . d j )]. Likewise, ligand-based distances between target pairs i and j were evaluated as the 133 cosine distance between the 50-dimensional vectors t i and t j corresponding to the two targets, the 134 entries of which are 0 or 1 depending on absence or existence of an interaction between the target and 135 the corresponding drug of abuse. 136
Probabilistic matrix factorization (PMF) based drug-target interaction prediction 137
Novel targets for each drug were predicted using our probabilistic matrix factorization ( for each predicted drug-target interaction, in both cases. We selected the interactions with confidence 149 scores higher than 0.7 within the top 10 predicted targets for each input drug. This led to 161 novel 150
interactions identified between 27 out of the 50 input drugs and 89 targets (composed of 41 known 151 and 48 novel targets) ( Supplementary Table 3 ). 152
Pathway enrichment analysis 153
We mapped the 50 drugs with 142 known and 48 predicted targets to the KEGG pathways (version 154
December 2017, homo sapiens) (Kanehisa et al., 2017) . 114 and 173 pathways were mapped by 142 155 known targets and all targets (both known and predicted) respectively (see Supplementary Table 4 ).
156
In order to prioritize enriched pathways, we calculated the hypergeometric p-values based on the 157 targets as the enrichment score as follows. Given a list of targets, the enrichment p-value for pathway 158 A (P A ) is the probability of randomly drawing k 0 or more targets that belong to pathway A: 159
where M is the total number of human proteins in the KEGG Pathway, m is the total number of 160 proteins/targets we identified, and K is the number of proteins that belong to pathway A, while k 0 is 161 the number of targets we identified that belong to pathway A. 162 Supplementary Table 1  170 and Supplementary Figure 1 . As expected, drugs belonging to the same functional category (same 171 color) exhibit more similar interaction patterns (panel D). However, we also note outliers, such as 172 cocaine lying among opioids, as opposed to its categorization as a CNS stimulant, or promethazine, a 173 CNS depressant, lying among hallucinogens (shown by arrows). The peculiar behavior of cocaine is 174 consistent with its high promiscuity (see Figure 2A for the number of targets associated with each 175 examined drug). This type of promiscuity becomes even more apparent when the drugs are organized 176
based on their structure (or 2D fingerprints; see Materials and Methods) as may be seen in panel A. 177
For example, opioids (clustered together in panels B and D based on their interactions) are now 178 distributed in two or more branches of the dendrogram (cyan labels/arc; panel C); likewise, CNS 179 depressants (blue) and cannabinoids (light brown), grouped each as a single cluster in panel D, are 180 now distributed into two or more clusters in panel C. 181
Overall these results suggest that the functional categorization of the drugs does not necessarily 182 comply with their structural characteristics. The similar functionality presumably originates from 183 targeting similar pathways, but the difference in the structure suggests that either their targets, or the 184 binding sites on the same target, are different; or the binding is not selective enough such that 185 multiple drugs can bind the same site. Consequently, a diversity of pathways or a multiplicity of 186 cellular responses are triggered by the use and abuse of these drugs. 187
The selected drugs and identified targets are highly diverse and promiscuous 188
We evaluated the similarities between proteins targeted by drugs of abuse, based on their interaction 189 patterns with the studied drugs of abuse. Figure 1 panels E and F display the respective target-target 190 distances, and corresponding dendrogram. Supplementary Table 2 lists the full names of these 191 targets, organized in the same order as the panel E axes. We discern several groups of targets 192 clustered together in consistency with their biological functions. For example, practically all GABA 193 receptor subtypes (brown) are clustered together. This large cluster also includes the riboflavin 194 transporter 2A (SLC52A2), which may be required for GABA release (Tritsch et al., 2012) . On the 195 other hand, the different subtypes of serotonin (or 5-hydroxytryptamine, 5-HT) receptors (5HTRs) 196 participate in distinct clusters pointing to the specificity of different subtypes vis-à-vis different drugs 197 of abuse (labeled in Figure 1F ). 198
The large majority of neurotransmitter transporters, such as Na + /Cl --dependent GABA transporters 199 (SLC6A1) and glycine transporter (SLC6A9) are in the same cluster (pink, labeled). Acetylcholine 200 receptors also lie close to (or are even interspersed among) Na + /Cl --dependent neurotransmitter 201 transporters, presumably due to shared drugs such as cocaine. However, the three transporters 202 playing a crucial role in developing drug addiction, DAT, NE transporter (NET) and serotonin 203 transporter (SERT) (labeled SLC6A2: NET, SLC6A3: DAT, SLC6A4: SERT) are distinguished by 204 from all other neurotransmitter transporters as a completely disjoint group. The corresponding branch 205 of the dendrogram (highlighted by the yellow circle) also includes vesicular amino acid transporters 206
and trace amine-associated receptor 1 (TAAR1) known to interact with these transporters (Miller, 207 2011) . We also note in the same branch two seemingly unrelated targets: flavin monoamine oxidase 208 This is a provisional file, not the final typeset article which draws attention to the role of oxidative events; and α2-adrenergic receptor subtypes A-C, 209
which uses NE as a chemical messenger for mediating stimulant effects such as sensitization and 210 reinstatement of drug seeking, and adenylate cyclase as another messenger to regulate cAMP levels 211 (Sofuoglu and Sewell, 2009 ). 212 Supplementary Table 2 summarizes the 445 known interactions between these 50 drugs and 142  213 targets. We observe an average of 8.9 interactions per drug and 3.1 interactions per target. There are 214 23 promiscuous drugs that target at least 10 proteins as shown in Figure 2 The PMF model enables us to predict novel targets. For example, anabolic steroid nandrolone has 223 only two known interactions, and cannabinoid cannabichromene has one. However, 10 new targets 224
were predicted with high confidence scores for each of them ( Supplementary Table 3 and 225 Supplementary Figure 2A ). This is due to the data available in STITCH DB, which offers a large 226
training dataset that enhances the performance of our machine learning approach. Overall, 89 new 227 interactions were predicted for known targets, and 42 novel targets were predicted with 72 228
interactions. Figure 2 panel C displays the distribution of all targets among different protein families. 229
As will be further elaborated below, among the newly identified drug-target pairs, nandrolone-230 MAPK14 (mitogen-activated protein kinase 14, also known as p38α) and canabichromene-IKBKB 231
(inhibitor of NFκ-B kinase subunit β) play a role in regulating mTORC1 signaling, which will be 232
shown to be an effector of drug addiction. 233
Turning to targets, three opioid receptors (OPRM1, OPRD1 and OPRL1) exhibit the highest level of 234 promiscuity (Supplementary Figure 2B) . The μ-type opioid receptor (OPRM1) interacts with 14 235
known drugs including all opioids as well as ketamine and dextromethorphan. We also predicted a 236 novel interaction between OPRM1 and the CNS stimulant methylphenidate. This is consistent with 237 experimental observations that methylphenidate upregulates OPRM1's activity in the reward 238 circuitry in a mouse model (Zhu et al., 2011). Furthermore, tissue-based transcriptome analysis 239 (Uhlén et al., 2015) shows that 69% of our 190 targets are expressed in the brain, and 49 of them 240
show elevated expression levels in the brain compared to other tissue types ( Supplementary Table  241 5). Among all the targets, NMDA receptor 1 (GRIN1) shows the highest elevated expression. It is 242 also one of the top 5 enriched genes overall in the brain (Uhlén et al., 2015) . 243
Taken together, the 50 selected drugs of abuse and the 142 known and 48 novel targets we identified 244 cover a diversity of biological functions, are involved in many cellular pathways, and are generally 245 promiscuous. In order to reveal the common mechanisms that underlie the development and 246 escalation of drug addiction and also distinguish the effects specific to selected drugs, we proceed 247 now to a detailed pathway analysis, presented next. 248
Pathway enrichment analysis reveals the major pathways implicated in various stages of 249 addiction development 250
Our QSP analysis yielded a total of 173 pathways, including 114 associated with the known targets 251 of the examined dataset of drugs of abuse, and 59 associated with the predicted targets. The detailed 252 pathway enrichment results can be found in Supplementary Table 4 . These pathways can be 253 grouped in five categories (Figure 3, Supplementary Figure 4 , and Supplementary 267 al., 2014). We note that many receptors targeted by drugs of abuse take part in the KEGG 268 neuroactive ligand-receptor interaction pathway. In the interest of focusing on intracellular signaling 269 effects, we have not included these in the SG category; they are listed in the 'Other Pathways' in 270 Supplementary Table 4 . 271
Autonomic nervous system (ANS)-innervation (ANS). We also identified 10 pathways regulating 272
ANS-innervated systems such as endocrine secretion, taste transduction, and circadian entrainment. contribute to the withdrawn symptoms associated with drug addiction. 37 known and 9 predicted 276 targets take part in these pathways. 277
Neuroplasticity (NP). Eight enriched pathways with potential to alter the morphology of neurons, 278
were found to be related to drug addiction. Among them, long-term potentiation (LTP) and long-term 279 depression (LTD) are key to reward-related learning and addiction by modifying the fine tuning of 280 dopaminergic firing (Jones and Bonci, 2005) . Axon guidance pathway regulates the growth direction 281 of neuron cells (Bahi and Dreyer, 2005) . Regulation of actin cytoskeleton plays important role in 282 morphological development and structural changes of neurons (Luo, 2002 Disease-associated pathways (DS). 50 enriched pathways are associated with diverse diseases in 291 different organs such as brain, liver, and lung. They also cover various drug addiction mechanisms 292
including: nicotine addiction, morphine addiction, cocaine addiction, amphetamine addiction, and 293 alcoholism. Additionally, there are 'other pathways' such as those involved in cell migration, 294 This is a provisional file, not the final typeset article differentiation, immune responses, and metabolic events, which can be seen in Supplementary  295  Table 4 . 296
Taken together, the enrichment analysis reveals five major categories of pathways that regulate the 297 three stages of drug addiction cycle: (1) binge and intoxication, (2) withdrawal and negative affect, 298
and (3) preoccupation and anticipation (or craving) (Koob and Volkow, 2010) . Drugs of abuse 299 directly affect neurotransmission pathways: they increase the accumulation of DA and other 300 neurotransmitters in the synaptic and extrasynaptic regions, which in turn results in the hedonic 301 feeling (stage 1) and triggers the DA reward system. Dysregulation of ANS-innervation pathways 302 may cause negative effects and feelings (stage 2) and feedback to the CNS. Addictive drugs impair 303 executive processes by disrupting the reward system (neurotransmission pathways) and imparting 304 morphological changes via neuroplasticity pathways (e.g. LTD and LTP), which then result in 305 craving (stage 3). Below, we present an in-depth analysis of the role of these pathways or their shared 306 targets in drug addiction. 307
Selected targets shared by dominant pathways emerge as common mediators of drug 308 addiction 309
We next analyzed the overlapping targets between the pathways in different functional categories. 310 We note in particular eight pleiotropic proteins involved in all five categories (at the intersection of 311 the 5 Venn diagrams in Figure 3B : AMPA receptor (subtype GluA2; GRIA2), NMDA receptors 1 312
and 2A-D (designated as GRIN1, GRIN2A, GRIN2B, GRIN2C and GRIN2D) and voltage-313 dependent calcium channel Ca v 2.1 (or CACNA1A) as well as the predicted target 314 phosphatidylinositol 3-kinase class 1A catalytic subunit α (PIK3CA) ( Supplementary Table 4 ). 315 Additionally, 15 proteins are distinguished as targets of four of these major pathways: Serotonin 316 receptors 5HTR2-A, -B and -C), GABA A receptors 1-6 (GABRA1-GABRA6), β-1 adrenergic 317 receptor 1 (ADRB1), Ras-related C3 botulinum toxin substrate 1 (RAC1; member of Rho family of 318
GTPases), mAChR M 3 (CHRM3) and DA receptor D 2 (DRD2) and two predicted targets p38α 319 (MAPK14) and DA receptor D 1 (DRD1 Likewise, GABARs are downstream mediators in the serotonergic synapse pathway. 358
In Figure 4 , we highlight five major neurotransmission events that directly mediate addiction, and 359 illustrate how eight drugs of abuse interfere with them. Despite the promiscuity of the drugs of abuse, 360 some selectively map onto a single synaptic neurotransmission pathway. For example, psilocin (a 361 hallucinogen whose structure is similar to 5HT (Diaz and Diaz, 1997)) interacts with several types of 362 5HTRs, regulating serotonergic synapse exclusively (see Figure 4 and Supplementary Table 4 ). In 363 contract, loperamide (not shown) affects all neurotransmission pathways by interacting with the 364 voltage-dependent P/Q-type calcium channel (VGCC), regulating calcium flux on synapses. Cocaine 365 targets four of these synaptic neurotransmission events (serotonergic, GABAergic, cholinergic, and 366 dopaminergic synapses), through its interactions with 5-HT3R, sodium-and chloride-dependent 367 GABA transporter (GAT), muscarinic (M1 and M2) and nicotinic AChRs, and DAT, respectively. 368
Methadone affects three synaptic neurotransmissions, including serotonergic synapse, dopaminergic 369 synapse and glutamatergic synapse through the interactions with SERT, DAT, and glutamate 370 receptors (NMDAR) respectively. 371
It is worth noting that predictions by our PMF model lead to a better understanding of the way drugs 372 of abuse affect neurotransmissions. In addition to the new role of M5 we discussed in Section 3.2, 373
our PMF model predicted that cannabichromene, a cannabinoid whose primary target is the transient 374 receptor (TRPA1), is found to interact with DAT and directly regulate dopaminergic transmission, 375 which will require further examination. Synaptic neurotransmission events act as upstream signaling 376 modules that 'sense' the early effects of drug abuse. In the next section, we focus on the downstream 377 signaling events elicited by drug abuse. 378
mTORC1 emerges as a downstream effector activated by drugs abuse 379
The calcium-, cAMP-, Rap1-, Ras-, AMPK-, ErbB-, MAPK-, and PI3K-Akt-signaling pathways in 380 the SG category ( Supplementary Table 4 ) crosstalk with each other and form a unified signaling 381 network. As shown in Figure 5 , ligand-binding to GPCRs modulates the production of cAMP, which This is a provisional file, not the final typeset article leads to the activation of Rap1. Activated Rap1 modules the Ca 2+ signaling by inducing the 383 production of inositol triphosphate (IP 3 ) and also activates the PI3K-Akt signaling cascade. 384
Stimulations of ErbB family of receptor tyrosine kinases (related to epidermal growth factor receptor 385 EGFR) as well as insulin-like growth factor receptor IGF1R trigger both PI3K-Akt and MAPK 386 signaling cascades (proteins colored blue in Figure 5 ). Notably all these pathways merge and 387 regulate a group of downstream proteins (shown in dark yellow in Figure 5) ; and at the center of this 388 cluster lies the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) which is likely to be 389 synergistically regulated by all these merging pathways. 390 mTORC1 is not only a master regulator of autophagy (Rabanal-Ruiz et al., 2017), but also controls 391 protein synthesis and transcription (Ma and Blenis, 2009 ). It has been reported to promote 392 neuroadaptation following exposure to drugs of abuse including cocaine, alcohol, morphine and Δ 9 -393 tetrahydrocannabinol (THC) (Neasta et al., 2014) . Our results suggest that mTORC1 may act as a 394
universal effector of the cellular response to drug abuse at an advanced (preoccupation and 395 anticipation, or craving) stage, controlling the synthesis of selected proteins and ensuing cell growth, 396
which may result in persistent alterations in the dendritic morphology and neuronal circuitry. 397
In Figure 5 , selected interactions between drugs from different substance groups and their targets are 398 highlighted using gray arrows. Our PMF model predicted that diazepam would interact with PI3K to 399 influence mTORC1 signaling (dashed gray arrows denote predictions). It has been reported that 400
Ro5-4864, a benzodiazepine derivative of diazepam suppresses activation of PI3K (Yousefi et al., 401 2013), which corroborates our prediction. We further predicted that cannabichromene may interact 402
with IκB kinase β (IKKβ) to regulate mTORC1 by inhibiting TSC1/2. Interestingly, another 403 cannabinoid arachidonoylethanolamine is known to directly inhibits IKKβ (Sancho et al., 2003) . 404
Taken together, our results identified a unified network that underlies the development of drugs 405 addiction, in which mTORC1 appears to play a key effector role. 406
4
Discussion 407
In the present study we focused on the targets and pathways affected by drugs of abuse, toward 408 gaining a systems-level understanding of key players and dominant interactions that control the 409 response to drug abuse and the development of drug addiction. Using machine learning methods, we 410 focused on 50 drugs of abuse that form a chemically and functionally diverse set, and analyzed their 411 142 targets as well as the corresponding cellular pathways and their crosstalk. Overall, our comprehensive analysis led to new hypotheses on drug-target interactions and signaling 424 and regulation mechanism elicited by drugs of abuse in general, along with those on selected targets and pathways for specific drugs. Below we elaborate on the biological and biomedical implications 426 of these findings. 427
Persistent restructuring in neuronal systems as a feature underlying drug addiction 428
Enriched pathways in the neuroplasticity category include gap junction, LTP, LDP, adherens 429 junction, regulation of actin cytoskeleton, focal adhesion, axon guidance, and tight junction 430
( Supplementary Table 4 . As will be further discussed below, mTORC1 plays a 441 central role in the synthesis of new proteins (e.g. AMPARs) and thereby neuronal (dendrites) growth, 442
alteration of the synaptic geometry and therefore rewiring of the neuronal circuitry. 443
ANS may mediate the negative-reinforcement of drug addiction 444
Our results further show that the pathways regulating ANS-innervated systems are associated with 445 drugs of abuse. As the NP pathways may influence the neuroplasticity in the ANS, we hypothesize 446 that drugs of abuse may induce the persistent restructuring in ANS as well. The drug-related 447 plasticity in ANS may lead to the dysregulation of ANS-innervated systems and cause negative 448 effects and feelings during the second stage of drug addiction. 449
Drug addiction is well known as a brain disease (Volkow and Morales, 2015) . However, many drugs 450 of abuse can disrupt the activity of ANS and cause disorders in ANS-innervated systems (Al-Hasani 451 and Bruchas, 2011; Huang, 2017). For example, opioids (e.g. morphine) alter neuronal excitability 452 and neurotransmission in the ANS (Wood and Galligan, 2004) , and induce disorders in 453
gastrointestinal system, smooth muscle, skin, cardiovascular, and immune system (Al-Hasani and 454
Bruchas, 2011). Cannabinoids (e.g. THC) modulate the exocytotic NE release in ANS-innervated 455 organs through presynaptic cannabinoid receptors (Ishac et al., 1996) . 456
The pathways we identified in the ANS category regulate insulin secretion, gastric acid secretion, 457 vascular smooth muscle contraction, pancreatic secretion, salivary secretion and renin secretion 458
( Supplementary Table 4 ). Their dysfunction may be associated with the autonomic withdrawal 459 syndrome, such as thermoregulatory disorder (chills and sweats) and gastrointestinal upset 460
(abdominal cramps and diarrhea), which has been observed in drug/substance users (Wise and Koob, 461 2014). In addition, the stress and depression caused by these negative effects may be part of the 462 negative reinforcement of drug addiction (Self and Nestler, 1995; Koob and Le Moal, 2001) . In other 463 words, the drug induced ANS disorders can feedback to CNS and mediate the negative 464 reinforcement. Compared to the structural changes in CNS, the disorder and persistent restructuring 465 in ANS is less studied and it could be a future direction in the study of development of drug addiction 466 and related diseases. 467 This is a provisional file, not the final typeset article 4.3 mTORC1 signaling plays a key role in mediating cellular morphological changes in 468 response to continued drug abuse 469
The functioning and regulation of mTOR signaling has been elucidated over the past two decades. It 470 became clear that mTORC1 plays a crucial role in regulating diverse cellular processes including 471 protein synthesis, autophagy, lipid metabolism, and mitochondrial biogenesis (Saxton and Sabatini, 472 2017). In the brain, mTORC1 coordinates neural development, circuit formation, synaptic plasticity, 473
and long-term memory (Lipton and Sahin, 2014) . The downstream effectors of mTORC1, which specifically mediate drug behavioral plasticity is far 496 from known. mTORC1 can mediate the activation of S6Ks and 4E-BPs, which leads to increased 497 production of proteins required for synaptic plasticity including AMPAR and PSD-95 (Dayas et al., 498 2012). EM reconstruction of hippocampal neuropil showed the variability in the size and shape of 499 dendrites depending on synaptic activity (Bartol Jr et al., 2015) , which in turn correlates with 500 information storage. Recently studies have revealed that Atg5-and Atg7-dependent autophagy in 501 dopaminergic neurons regulates cellular and behavioral responses to morphine (Su et al., 2017) . 502
Cocaine exposure results in ER stress-induced and mTORC1-dependent autophagy (Guo et al., 503 2015) . Fentanyl induces autophagy via activation of ROS/MAPK pathway (Yao et al., 2016) . 504
Methamphetamine induces autophagy through the κ -opioid receptor (Ma et al., 2014) . These 505 observations are all consistent with the conclusion drawn here with regard to the role of mTORC1 as 506 a major effector of cellular responses to drug addiction. 507
Drug repurposing opportunities for combatting drug addiction 508
Autophagy modulating drugs have been shown to have therapeutic effects against liver and lung 509 diseases. The signaling network presented in Figure 5 involves many targets of such drugs. For 510 instance, carbamazepine affects IP 3 production and enhances autophagy via calcium-AMPK-511 mTORC1 pathway (Hidvegi et al., 2010) . It has been identified as a potential drug for treating α 1-512 antitrypsin deficiency, hepatic fibrosis, and lung proteinopathy (Hidvegi et al., 2010; Hidvegi et al., 513 2015) . Rapamycin is a potential drug for lung disease such as fibrosis (Abdulrahman et al., 2011; 514 Patel et al., 2012) . Other liver and lung drugs which facilitate the removal of aggregates by 515 promoting autophagy may also affect drug-related neurodegenerative disorders. Supplementary 516 Table 7 summarizes 15 autophagy-modulating drugs for liver and lung diseases. Target identification 517
and pathway analysis of this subset of drugs using the same protocol as those adopted for the 50 518 drugs of abuse indeed confirmed that drugs of abuse and liver/lung drugs share many common 519 pathways (Supplementary Figure 5) . Notably, among those pathways, neuroactive ligand-receptor 520
interactions, calcium signaling, and serotonergic synapse pathways are among the top 10 enriched 521 pathways of both drugs of abuse and liver/lung drugs. Amphetamine addiction and alcoholism are 522 also enriched by targets of liver/lung drugs. Thus, an interesting future direction is to examine 523 whether autophagy modulating drugs for liver and lung diseases could be repurposed, if necessary by 524 suitable refinements to increase their selectivity, for treating drug addiction. 525 5
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